司美替尼|T6218

Selumetinib
606143-52-6

￥349 25mg 起订

￥498 50mg 起订

￥813 100mg 起订

上海更新日期：2025-03-12

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 司美替尼

英文名称：: Selumetinib

CAS号：: 606143-52-6

品牌：: TargetMol

产地：: 美国

保存条件：: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.46%

产品类别：: 抑制剂

货号：: T6218

Product Introduction

Bioactivity

名称	Selumetinib
描述	Selumetinib (AZD6244) is a MEK1/2 inhibitor that inhibits MEK1 (IC50=14 nM) with potent selectivity and is non-ATP-competitive. Selumetinib has antitumor activity and is used for the treatment of neurofibromatosis type 1 (NF1).
细胞实验	Primary HCC cells were plated at a density of 2.0 × 10^4 per well in growth medium. After 48 h in growth medium, the cell monolayer was rinsed twice with MEM. Cells were treated with various concentrations of AZD6244 (0, 0.5, 1.0, 2.0, 3.0, and 4.0 μmol/L) for 24 or 48 h. Cell viability was determined by the MTT assay. Cell proliferation was assayed using a bromodeoxyuridine kit as described by the manufacturer. Experiments were repeated at least thrice, and the data were expressed as mean ± SE [2].
激酶实验	NH2-terminal hexahistidine tagged, constitutively active MEK1 was expressed in baculovirus-infected Hi5 insect cells and purified by immobilized metal affinity chromatography, ion exchange, and gel filtration. The activity of MEK1 was assessed by measuring the incorporation of [γ-33P]phosphate from [γ-33P]ATP onto ERK2. The assay was carried out in a 96-well polypropylene plate with an incubation mixture (100 μL) composed of 25 mmol/L HEPES (pH 7.4), 10 mmol/L MgCl2, 5 mmol/L β-glycerolphosphate, 100 μmol/L sodium orthovanadate, 5 mmol/L DTT, 5 nmol/L MEK1, 1 μmol/L ERK2, and 0 to 80 nmol/L compound (final concentration of 1% DMSO). The reactions were initiated by the addition of 10 μmol/L ATP (with 0.5 μC k[γ-33P]ATP/well) and incubated at room temperature for 45 min. An equal volume of 25% trichloracetic acid was added to stop the reaction and precipitate the proteins. Precipitated proteins were trapped onto glass fiber B filter plates, excess labeled ATP was washed off with 0.5% phosphoric acid, and radioactivity was counted in a liquid scintillation counter. ATP dependence was determined by varying the amount of ATP in the reaction mixture. The data were globally fitted using SigmaPlot. Values were calculated using the following equation for noncompetitive inhibition: v = [Vmax × S / (1 + I / Ki)] / (Km + S) [1].
动物实验	HT-29 human colon carcinoma or BxPC3 human pancreatic tumor fragments were implanted s.c. in the flank of nude mice and allowed to grow to 100 to 150 mg. Mice (n = 10 per group) were randomized to treatment groups to receive vehicle (10 mL/kg and 10% ethanol/10% cremophor EL/80% D5W) or ARRY-142886 (10, 25, 50, or 100 mg/kg, oral, BID) on days 1 to 21. Tumors [(W^2 × L) / L] were measured twice weekly. Tumor growth inhibition was calculated as 1 ? (tumor sizetreated / tumor sizevehicle) on each measurement day. Four hours after the last dose on day 21, three mice per group were euthanized to evaluate pharmacokinetic/pharmacodynamic responses. Tumors were excised and flash frozen. Homogenates were analyzed for phospho-ERK1/2 and ERK1/2 expression by Western blotting as described above. For the HT-29 study, monitoring of tumor regrowth was continued for the remaining seven mice per group until tumors reached 1,000 mm^3, when mice would be sacrificed. There were two BxPC3 tumor xenograft studies. For the first study, one group of mice was treated with the clinical standard of care, gemcitabine, at 160 mg/kg, i.p., every 3rd day for a total of four doses. This dose was determined to be the maximum tolerated dose for gemcitabine in the BxPC3 model on this dosing schedule. To evaluate whether previously treated tumors would be refractory to a second cycle of treatment, a second BxPC3 xenograft study was carried out. Mice were treated with vehicle or ARRY-142886 at 25 or 50 mg/kg, BID, for 21 days. Treatment was stopped and tumors were allowed to grow for an additional 7 days before treatment resumed for another 21-day cycle [1].
体外活性	方法: TNBC 细胞系 MDA-MB-231、MDA-MB-468、SUM149、SUM190、KPL-4、MDA-IBC-3 用 Selumetinib (0-100 µM) 处理 72 h，通过 WST-1 assay 检测细胞活力。结果: 在 MDA-MB-468、SUM190、KPL-4 和 MDA-IBC-3细胞中，IC50 在 20 µM 以上，在 MDA-MAB-231 和 SUM149 细胞中， IC50 值分别为 8.6 µM 和 10 µM。[1] 方法: 乳腺癌细胞 HCC-1937 和 MDA-MB-231 用 Selumetinib (1-50 µM) 处理 24 h，通过 Flow cytometry 检测细胞周期。结果: Selumetinib 以剂量依赖的方式触发细胞凋亡和 G1 期阻滞。[2]
体内活性	方法: 为检测体内抗肿瘤活性，将 Selumetinib (50 mg/kg，0.5% hydroxypropyl methyl cellulose and 0.1% Tween 80) 灌胃给药给携带 MDA-MB-231-LM2 异种移植物的 athymic nu/nu 小鼠，每周五次，持续三周。结果: 在用 Selumetinib 治疗的小鼠中，肺转移受到抑制，肿瘤细胞从间充质表型逆转为上皮表型。[1]
存储条件	store at low temperature \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 1 mg/mL, Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble)
关键字	inhibit \| ARRY142886 \| AZD 6244 \| MAP2K \| ARRY 142886 \| MAPKK \| Mitogen-activated protein kinase kinase \| Inhibitor \| AZD-6244 \| Selumetinib \| Apoptosis \| MEK
相关产品	L-Glutamic acid \| Metronidazole \| 5-Fluorouracil \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| Tributyrin \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Salicylic acid \| Sodium 4-phenylbutyrate
相关库	抑制剂库 \| 抗癌上市药物库 \| 激酶抑制剂库 \| EMA 上市药物库 \| 抗衰老化合物库 \| 高选择性抑制剂库 \| FDA 上市激酶抑制剂库 \| 疼痛相关化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

司美替尼|||AZD6244|||ARRY-142886|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子